Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Dec;10(4):232-5.
doi: 10.7497/j.issn.2095-3941.2013.04.008.

Rare myeloid sarcoma/acute myeloid leukemia with adrenal mass after allogeneic mobilization peripheral blood stem cell transplantation

Ya-Fei Wang  1 , Qian Li  1 , Wen-Gui Xu  2 , Jian-Yu Xiao  3 , Qing-Song Pang  4 , Qing Yang  5 , Yi-Zuo Zhang  1
Affiliations
Case Reports

Rare myeloid sarcoma/acute myeloid leukemia with adrenal mass after allogeneic mobilization peripheral blood stem cell transplantation

Ya-Fei Wang et al. Cancer Biol Med. 2013 Dec.

Abstract

Myeloid sarcoma (MS) is a rare hematological neoplasm that develops either de novo or concurrently with acute myeloid leukemia (AML). This neoplasm can also be an initial manifestation of relapse in a previously treated AML that is in remission. A 44-year-old male patient was diagnosed with testis MS in a local hospital in August 2010. After one month, bone marrow biopsy and aspiration confirmed the diagnosis of AML. Allogeneic mobilization peripheral blood stem cell transplantation was performed, with the sister of the patient as donor, after complete remission (CR) was achieved by chemotherapy. Five months after treatment, an adrenal mass was detected by positron emission tomography-computed tomography (PET-CT). Radiotherapy was performed for the localized mass after a multidisciplinary team (MDT) discussion. The patient is still alive as of May 2013, with no evidence of recurrent MS or leukemia.

Keywords: Myeloid sarcoma (MS); acute myeloid leukemia (AML); allogeneic hematopoietic stem cell transplantation; multidisciplinary team (MDT).

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

Figure 1
Figure 1
FDG PET-CT results. A, FDG uptake in the right adrenal gland before irradiation. B, FDG uptake disappeared in the right adrenal gland (arrow) after irradiation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Klco JM, Welch JS, Nguyen TT, Hurley MY, Kreisel FH, Hassan A, et al. State of the art in myeloid sarcoma. Int J Lab Hematol 2011;33:555-565 - PubMed
    1. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007;21:340-350 - PubMed
    1. The International Agency for Research on Cancer eds. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. IARC Press, Lyon, 2008;140-141.
    1. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 2. 2012.
    1. Low G, Dhliwayo H, Lomas DJ. Adrenal neoplasms. Clin Radiol 2012;67:988-1000 - PubMed

Publication types

LinkOut - more resources